Inactive Instrument

Analyst Reco. Immunovant, Inc. Nasdaq

Equities

US45258J2015

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing	04-19	MT
Immunovant Insider Sold Shares Worth $293,923, According to a Recent SEC Filing	04-19	MT
Oppenheimer Initiates Coverage on Immunovant With Outperform Rating, $50 Price Target	03-28	MT
Goldman Sachs Starts Coverage on Immunovant With Buy Rating, $50 Price Target	03-13	MT
JPMorgan Starts Coverage on Immunovant With Overweight Rating, $51 Price Target	02-20	MT
Wolfe Research Starts Immunovant With Outperform Rating, $55 Price Target	02-15	MT
HC Wainwright Adjusts Price Target on Immunovant to $51 From $47, Keeps Buy Rating	12-21	MT
Immunovant's Batoclimab for Graves' Disease Produces Meaningful Response Rates in Study; Shares Jump After Hours	12-20	MT
Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates	12-20	CI
Deutsche Bank Initiates Coverage on Immunovant With Buy Rating, $50 Price Target	12-12	MT
UBS Raises Immunovant Price Target to $56 From $55, Maintains Buy Rating	12-01	MT
Truist Adjusts Price Target on Immunovant to $48 From $30, Maintains Buy Rating	11-15	MT
Piper Sandler Adjusts Immunovant's Price Target to $57 From $28, Maintains Overweight Rating	24/10/23	MT
HC Wainwright Adjusts Immunovant Price Target to $47 From $29, Maintains Buy Rating	24/10/23	MT
UBS Upgrades Immunovant to Buy From Neutral, Adjusts Price Target to $55 From $18	13/10/23	MT
Wall St. pounded as investors grapple with higher rates	26/09/23	RE
Citigroup Raises Immunovant Price Target to $50 From $33, Maintains Buy Rating	26/09/23	MT
Wall St slides as rate concerns keep Treasury yields near 16-year peak	26/09/23	RE
Raymond James Upgrades Immunovant to Outperform From Market Perform, $40 Price Target	26/09/23	MT
Wells Fargo Adjusts Immunovant Price Target to $48 From $33, Maintains Overweight Rating	26/09/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Immunovant, Inc. Nasdaq

Equities

US45258J2015

Analyst Reco.

Filters